A software-implemented business method could be patentable if programmed into a computer with “some ingenuity”, IP Australia told the Full Federal Court as a landmark appeal between rival tech companies Encompass and Infotrack wrapped up Friday.
Fintech company Encompass has asked the Full Federal Court to take a more “nuanced” approach to software patentability than the one currently held by IP Australia, on the first day of a high-stakes appeal over the patentability of computer-related inventions.
The Federal Court will hear a dispute between Fueltrac and the State of Queensland over the copyright for the fuel data reporting company’s monthly pump price report.
Shenzen-based radio manufacturer Hytera Communications has lost a bid to circumvent its discovery obligations in an ongoing patent dispute with Motorola, with a Federal Court judge rejecting its claims that supplying the documents could breach Chinese state secret and cybersecurity laws.
A group representing Australian winemakers has lost its objection to the European Commission’s plan to register ‘Avola’ as a mark of geographical indication for wine.
The Commonwealth of Australia is weighing a bid to strike out Otsuka Pharmaceutical’s defence as the government seeks lost subsidies after an almost seven-year long patent dispute over the antipsychotic drug, Abilify.
An education provider calling itself Trinity College Australia faces a lawsuit alleging it is duping consumers by trying to pass off as The University of Melbourne’s famed residential college.
Australian coffee maker Vittoria Food & Beverage has won another challenge to a patent for a coffee pod system filed by a unit of Mondelez International.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
Generic Health has shaved two percent off the $25 million damages awarded pharmaceutical giant Bayer in a patent infringement case over Bayer’s blockbuster oral contraceptive, Yasmin, but the discount is a far cry from the 15 percent it sought on appeal.